Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Nelarabine is in a class of medications called antimetabolites
Subscribe To Our Newsletter & Stay Updated